Related references
Note: Only part of the references are listed.Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma
Paolo A. Ascierto et al.
EUROPEAN JOURNAL OF CANCER (2020)
Targeted Therapy in Melanoma and Mechanisms of Resistance
Anna M. Czarnecka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Iovance generation-2 tumour-infiltrating lymphocyte (TIL) product is reinvigorated during the manufacturing process
M. R. Simpson-Abelson et al.
ANNALS OF ONCOLOGY (2020)
y SAFETY & EFFICACY OF LIFILEUCEL (LN-144) TUMOR INFILTRATING LYMPHOCYTE THERAPY IN METASTATIC MELANOMA PATIENTS AFTER PROGRESSION ON MULTIPLE THERAPIES - INDEPENDENT REVIEW COMMITTEE DATA UPDATE
Amod Sarnaik et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition
Elizabeth I. Buchbinder et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
Yochai Wolf et al.
CELL (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
1310OAdjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial
J S Weber et al.
ANNALS OF ONCOLOGY (2019)
Cancer Neoantigens
Ton N. Schumacher et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 37, 2019 (2019)
Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma
Viktoria Gontcharova et al.
CANCER RESEARCH (2019)
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
James Larkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
Daniela S. Thommen et al.
NATURE MEDICINE (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series.
Simone M. Goldinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena J. Orlando et al.
NATURE MEDICINE (2018)
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Tuba N. Gide et al.
CLINICAL CANCER RESEARCH (2018)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G. V. Long et al.
ANNALS OF ONCOLOGY (2017)
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
Stephanie L. Goff et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
Cyrille J. Cohen et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
Yong-Chen Lu et al.
CLINICAL CANCER RESEARCH (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients
Laszlo G. Radvanyi et al.
CLINICAL CANCER RESEARCH (2012)
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
Eva Ellebaek et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Steven A. Rosenberg et al.
CLINICAL CANCER RESEARCH (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)